drugset / Trial / NCT05156892
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
Phase 1
Active not recruiting
44 enrolled
Anthony Joshua, FRACP
Concord Hospital · collabPrince of Wales Hospital, Sydney · collabRoyal Prince Alfred Hospital, Sydney, Australia · collabSt Vincent's Hospital, Sydney · collab
NaSequentialOpen-labelTreatment
Summary
The study's purpose is to understand the effects of a new treatment (suba-itraconazole and tamoxifen) in epithelial ovarian cancer. Who is it for? Patients may be eligible to join this study with ovarian cancer resistant to platinum-based chemotherapy agents Study Details: Participants will receive different doses of tamoxifen and suba-itraconazole to determine the optimal combination dose. Participants will be seen by the investigators once a week for the first 3 weeks and then once every 4 weeks. Participant will be reviewed by a clinician and undergo regular blood tests, cardiac monitoring and imaging assessments.
Timeline
- Start
- 2022-09-04
- Primary completion
- 2026-01-01
- Completion
- 2027-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Itraconazole | Small molecule | 150 mg | Oral |
| Subject | Tamoxifen | Small molecule | 20 mg | Oral |
| Subject | Tamoxifen | Small molecule | 40 mg | Oral |
| Subject | Tamoxifen | Small molecule | 60 mg | Oral |